VCT To Exhibit at World Vaccine Congress
Vaccine clinical trials pose unique challenges with regards to duplicate research subjects or professional subjects. Typically, large numbers of subjects are dosed at the first visit in a vaccine clinical trial. There is no way for a site or principal investigator to adequately check if the research subject is a duplicate or professional subject. Subjects
Duplicate Subjects in Clinical Trials Proactively Detected and Prevented By Verified Clinical Trials
There are many obstacles to the success of a clinical trial and duplicate research subjects, or professional research subjects are unfortunately one of them. Duplicate subjects in clinical trials results in a myriad of poor outcomes. Ultimately duplicate research subjects can result in a clinical trial failing to meet its endpoints. And now with decentralized
Duplicate Subjects In Clinical Trials and Decentralized Clinical Trials. Unique Issues With Professional Research Subjects
Interest in decentralized clinical trials has increased and has become quite popular. The adoption of these methods became acutely more appealing and necessary during the pandemic. Many research sites and clinical trial sponsors have adopted decentralized clinical trial methods. But decentralized clinical trials also come with unique challenges. To keep clinical trials safe, compliant, and effective,
Why A Research Subject Database Is Critical To Prevent Professional Research Subjects In Clinical Trials
Clinical trials rely upon speed and accuracy to deliver new drugs and medicines to the public. Limiting the potential for unwanted variables that can skew the data is critical. One of these issues is professional research subjects or duplicate subjects in clinical trials. These particular participants often times have motives to partiicapte in the particular
The Professional Research Subject Problem In Clinical Trials
Clinical research patients are compensated for their participation in clinical trials. In some therapeutic areas and types of clinical trials, the compensation for enrolling in one or more clinical trials or at multiple research sites is enough to influence patients to join more than one contemporaneously and expose themselves to multiple investigational products or multiple
RESEARCH SITES AND SPONSORS COOPERATE TO PREVENT PROFESSIONAL RESEARCH SUBJECTS IN CNS CLINICAL TRIALS BY USING VERIFIED CLINICAL TRIALS
Duplicate subjects, or what is known as professional research subjects, exist in most clinical trials to varying degrees. CNS clinical trials are especially prone to duplicate subjects or over enrollment in clinical tials. The issue exists from phase 1 healthy volunteer studies to multiple phase 2/3 clinical trials across many therapeutic indications. Use of global
